NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeoGenomics reports robust Q4 earnings, targets profitability in 2023

NeoGenomics delivered strong financial performance in Q4 2022 and full-year 2022, with a focus on sustainable long-term growth. The company aims to achieve adjusted EBITDA positive by Q4 2023 through strategic initiatives, including revenue growth, margin improvement, and operational efficiencies.

NeoGenomics reports robust Q1 results, eyes growth in diagnostics

NeoGenomics' Q1 performance reflects strong revenue growth and operational improvements, driven by strategic priorities and salesforce optimization.
While facing challenges in market share capture and modalities impact, the company's focus on automation and revenue cycle management presents growth opportunities.
Overall, NeoGenomics is well-positioned to achieve its full-year guidance and capitalize on opportunities in advanced diagnostics and revenue optimization.

NeoGenomics excels in Q2, raises guidance on strong growth prospects

NeoGenomics delivered strong financial results, raised revenue guidance, and improved operational efficiencies. With a focus on NGS portfolio expansion, revenue growth, and strategic planning, the company is well-positioned for future success amidst market challenges.

NeoGenomics reports strong Q3 growth, eyes accelerated breast coverage

NeoGenomics demonstrated robust growth and operational improvements in Q3.
The company's focus on high-value areas like breast cancer is a strategic advantage.
Challenges include potential delays in submissions and ongoing labor inflation concerns.
Opportunities lie in accelerated breast coverage, sales force expansion, and payment efficiency enhancements.

NeoGenomics reports strong Q4 earnings and outlines growth strategies

NeoGenomics delivered strong financial performance in Q4 2023, with revenue growth, improved profitability, and a focus on strategic investments for future growth and operational efficiency.
The company's strengths lie in its strategic focus areas, commitment to value creation, and solid financial position, positioning it well for sustainable success and market leadership.
While facing challenges such as market dynamics and operational hurdles, NeoGenomics has opportunities in expanding market share, product innovation, and strategic partnerships to drive growth and profitability.
Overall, NeoGenomics' performance, strengths, challenges, and opportunities indicate a resilient business poised for continued growth, profitability, and market expansion in the evolving healthcare landscape.

NeoGenomics reports robust Q1 growth, eyes M&A and innovation

NeoGenomics delivered strong financial performance in Q1 2024, driven by revenue growth and operational improvements.
The company's strategic priorities, leadership enhancements, and regulatory outlook bode well for future growth and innovation.
While facing challenges in legal defense and market dynamics, NeoGenomics is well-positioned to leverage opportunities in M&A, product launches, and commercial expansion.

NeoGenomics reports robust Q2 growth amidst legal challenges

NeoGenomics delivered strong financial performance in Q2 2024, with revenue growth, positive adjusted EBITDA, and raised revenue guidance for the year.
The company's strategic focus on innovation, operational efficiency, and growth positions it well to capitalize on the evolving healthcare landscape and increasing demand for advanced diagnostics.
While facing legal challenges, NeoGenomics is actively exploring solutions and remains committed to driving value creation and expanding its market presence through product development and strategic initiatives.

NeoGenomics reports record Q3 earnings, eyes growth through innovation

NeoGenomics delivered strong financial performance in Q3 2024, with record revenues and improved adjusted EBITDA, driven by NGS growth.
The company's strategic focus on sustainable growth, innovation, and financial management strengths position it well for future success.
Challenges lie in addressing profitability evolution, successful Neo Helix integration, and balancing short-term impact with long-term value creation.
Opportunities include Neo Helix development, revenue mix diversification, and achieving the revised adjusted EBITDA guidance range.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FT. MYERS, FL / ACCESSWIRE / January 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, Dr. Lawrence Weiss, Chief Medical Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the virtual 39th Annual J.P. Morgan Healthcare Conference 2021 on Monday, January 11, 2021 at 5:20pm ET.

NeoGenomics To Virtually Participate In The 39th Annual J.P. Morgan Healthcare Conference

Costco

MKS Instruments

Twitter

Zynga

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Costco and Twitter

Top Wall Street analysts recommend these buys before 2020 comes to a close

NeoGenomics remains insulated and differentiated from peers via a plethora of offerings in clinical diagnostics, as a potential market-leader in oncology services. The growth vision looks at consolidating a myriad of oncology diagnostics under one roof via clinical and pharmaceutical services, both of which are meaningful compounders.

NeoGenomics: ~27% Upside Potential Is Under-Reflected, Market Is Unfairly Discounting Shares

Insmed

Aurinia Pharmaceuticals

Cytokinetics

Turning Point Therapeutics

In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the  Top 5 Healthcare Stocks for the Future .

Top 10 Healthcare Stocks for the Future

NeoGenomics, Inc.'s (NEO) CEO Doug VanOort on Q3 2020 Results - Earnings Call Transcript

NeoGenomics (NEO) delivered earnings and revenue surprises of 500.00% and -2.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Surpasses Q3 Earnings Estimates

NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

NeoGenomics (NEO) Looks Good: Stock Adds 5.5% in Session

Anika Therapeutics

ANIK vs. NEO: Which Stock Is the Better Value Option?

The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.

NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound

NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q2 2020 Results - Earnings Call Transcript

NeoGenomics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
The post NeoGenomics Shows Market Leadership With Jump To 81 RS Rating appeared first on Investor's Business Daily.

NeoGenomics Shows Market Leadership With Jump To 81 RS Rating

A Relative Strength Rating upgrade for NeoGenomics shows improving technical performance. Will it continue?

Stocks Showing Improved Relative Strength: NeoGenomics

2 Stocks to Buy and Hold for Decades

The company decided to pull the trigger on a combined offering of stock and debt to pad its balance sheet during uncertain times.

Here's Why NeoGenomics Is Tumbling Today

Despite experiencing a double-digit decline in test volumes, the cancer genetics lab hasn't furloughed employees. It has even retooled labs to process COVID-19 swab and blood tests.

NeoGenomics Prioritizes the Public Good During COVID-19 Slowdown

Neogenomics Inc. (NEO) CEO Doug VanOort on Q1 2020 Results - Earnings Call Transcript

NeoGenomics (NEO) delivered earnings and revenue surprises of -200.00% and -0.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Reports Q1 Loss, Misses Revenue Estimates

Test volumes fell by double digits at the end of March compared with the year-ago period. How long does management think that trend will continue?

The Most Important Thing to Watch When NeoGenomics Reports Earnings

Exact Sciences

Invitae

Investors should prepare for the genetic testing industry to see a tangible slowdown in volumes due to the coronavirus pandemic.

Here's Why Genetic Testing Stocks Are Down Today

Growth stocks have been getting punished in the current market downturn, but investors with a long-term mindset will find plenty to like in the latest earnings report.

Strong Growth From NeoGenomics No Match for Economic Anxieties

Advances in precision medicine continue to propel the leader in oncology testing services.

NeoGenomics Reports Strong Growth but Gives a Weak Profit Outlook

The cancer genetics company reported full-year 2019 operating results, but that's probably not the reason for the decline.

Here's Why NeoGenomics Fell as Much as 20.2% Today

NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q4 2019 Results - Earnings Call Transcript

NeoGenomics (NEO) delivered earnings and revenue surprises of 42.86% and 2.31%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Tops Q4 Earnings and Revenue Estimates

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for NeoGenomics Stock (NEO)